灯盏细辛联合依帕司他对糖尿病肾病大鼠肾皮质中CAT、SOD、MDA表达的影响

Effect of Erigeron Breviscapus Combined with Epalrestat on the Expression of CAT,SOD,MDA in Renal Cortex of Diabetes Nephropathy Rats

目的:探究灯盏细辛联合依帕司他对糖尿病肾病(DN)大鼠CAT、SOD、MDA表达的影响,探讨其抗氧化应激的作用。方法:将50只SD大鼠随机分为正常对照组、模型组、灯盏细辛组、依帕司他组以及联合组,每组10只。除正常对照组外,其余各组采用喂养高脂高糖饲料、辅助一次性注射链脲佐菌素(STZ,55 mg/kg)的方法建立糖尿病肾病模型大鼠。造模成功后,依帕司他组给予依帕司他(100 mg/kg)灌胃,灯盏细辛组给予灯盏细辛(200 mg/kg)灌胃,联合组给予依帕司他(100 mg/kg)和灯盏细辛(200 mg/kg)灌胃,正常对照组和模型组给予5%CMC-Na混悬液灌胃,持续6周。记录造模前与治疗过程中各组大鼠的体质量、血糖以及24 h微量白蛋白(24 h UmAlb)含量;给药6周后处死大鼠,采用钼酸铵法检测肾皮质中过氧化氢酶(CAT)活性,采用WST1法检测大鼠肾皮质中超氧化物歧化酶(SOD)活性,采用TBA法检测肾皮质中丙二醛(MDA)含量。结果:治疗后6周末,与模型组比较,联合组大鼠体质量与模型组比较,上升最显著(P<0.01),其次是依帕司他组,最后是灯盏细辛组,联合组与依帕司他组、灯盏细辛组比较具有统计学意义(P<0.05,P<0.01);治疗后6周末,联合组的血糖,24 h UmAlb水平显著低于模型组、依帕司他组和灯盏细辛组(P<0.01,P<0.05);治疗后6周末,各组大鼠肾皮质氧化应激指标CAT、SOD和MDA水平比较,联合组大鼠肾皮质CAT和SOD水平明显高于模型组、依帕司他组和灯盏细辛组(P<0.01,P<0.05),MDA水平明显低于模型组、依帕司他组和灯盏细辛组(P<0.01,P<0.05)。结论:灯盏细辛联合依帕司他能有效纠正糖尿病肾病肾损伤,延缓病情发展,其机制可能与其上调CAT、SOD活性,降低MDA含量,进而调控糖尿病肾病肾组织氧化应激有关。

Objective:To explore the effects of Erigeron breviscapus combined with epalrestat on the expression of CAT,SOD and MDA in diabetic nephropathy(DN)rats and its anti-oxidative stress effect.Methods:Fifty SD rats were randomly divided into normal control group,model group,erigeron breviscapus group,epalrestat group,and combination group,with 10 rats in each group.The rats in all groups but the normal control one were fed with high-fat and high-sugar diet supplemented with one time injection of streptozotocin(STZ)to establish the model of diabetes nephropathy.After successful modeling,the rats in epalrestat group were given epalrestat(100 mg/kg)by gavage,erigeron breviscapus was gavaged to the rats in erigeron breviscapus group(200 mg/kg),the rats in combination group were administered with epalrestat(100 mg/kg)and erigeron breviscapus(200 mg/kg)by gavage,and the rats in normal control group and model group were given 5%CMC Na suspension by gavage,for 6 weeks.The rat′s the body weight,blood glucose,and 24-hour microalbumin(24 h UmAlb)content of each group were recorded before modeling and during the treatment.After 6 weeks of the administration,the rats were euthanized.The activity of catalase(CAT)in the renal cortex was measured using the ammonium molybdate method,the activity of superoxide dismutase(SOD)by the WST1 method,and the content of malondialdehyde(MDA)through the TBA method.Results:At the end of 6th week after treatment,the weight of rats in the combination group increased most significantly compared to the model group(P<0.01),followed by epalrestat group,and then by erigeron breviscapus group.The combination group had a statistically significant increase compared to epalrestat group and erigeron breviscapus group(P<0.05,P<0.05).At the end of 6th week after treatment,the blood glucose and 24 h UmAlb levels in the combination group were significantly lower than those in the model group,epalrestat group and erigeron breviscapus group(P<0.01,P<0.05).At the end of 6th week after the treatment,the levels of CAT,SOD,and MDA in the renal cortex of rats in each group were compared.The levels of CAT and SOD in the renal cortex of rats in the combination group were significantly higher than those in the model group,epalrestat group,and erigeron breviscapus group(P<0.01,P<0.05),while the level of MDA was significantly lower than that in the model group,epalrestat group,and erigeron breviscapus group(P<0.01,P<0.05).Conclusion:Erigeron breviscapus combined with epalrestat can effectively correct the renal injury of diabetes nephropathy and delay the development of the disease,the mechanism of which may be related to the up regulation of CAT and SOD activities,the reduction of MDA content and the regulation of oxidative stress in renal tissue of diabetes nephropathy.